文献速递白血病

靶向平行测序检测残留病灶可预测细胞遗传学正常急性髓系白血病的复发

Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2017-10-19

该先导研究纳入34例细胞遗传学正常AML患者,采用Ion Torrent平台靶向平行测序检测19个基因突变,并以数字PCR和条码测序验证。巩固治疗后非DNMT3A突变持续存在与更高复发风险(8例中7例 vs 19例中6例,P=0.013)及更短无复发生存(333天 vs 未达到,log-rank P=0.0219)相关。

要点

  • 巩固治疗后非DNMT3A体细胞突变持续存在与CN-AML复发风险升高相关(P=0.013)。
  • 非DNMT3A突变持续存在组无复发生存缩短(333天 vs 未达到,log-rank P=0.0219)。
  • 靶向平行测序检测残留病灶可行且有效,可靠灵敏度为0.5%。

核心结论

  • 靶向平行测序检测残留病灶可行且有效,非DNMT3A体细胞突变持续存在是CN-AML复发的预后因素。

研究设计与样本

  • 先导研究纳入34例细胞遗传学正常AML患者,诊断材料和至少1个巩固疗程后的缓解骨髓玻片可用。
  • 采用Ion Torrent测序平台筛查19个基因突变,并用数字PCR和条码测序验证突变等位基因频率。
  • 34例中27例可进行突变清除分析。

主要发现

  • 诊断时鉴定出68个体细胞突变(每例中位3个,范围1-5)。
  • 巩固治疗后16例患者中仍检出22个突变(可靠灵敏度0.5%,每例中位1个,范围0-3)。
  • 最常见的未清除突变位于DNMT3A。
  • 排除DNMT3A突变后,非DNMT3A突变持续存在与更高AML复发风险相关(8例中7例 vs 19例中6例,P=0.013)。
  • 非DNMT3A突变持续存在与更短无复发生存相关(333天 vs 未达到,log-rank P=0.0219)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite achieving complete remission after intensive therapy, most patients with cytogenetically normal (CN) AML relapse due to the persistence of submicroscopic residual disease. In this pilot study, we hypothesized that detection of leukemia-specific mutations following consolidation treatment using a targeted parallel sequencing approach predicts relapse. We included 34 AML patients of whom diagnostic material and remission bone marrow slides after at least one cycle of consolidation were available. Isolated DNA was screened for mutations in 19 genes using an Ion Torrent sequencing platform. Furthermore, the variant allelic frequency of distinct mutations was validated by digital PCR and sequencing using a barcoding approach. Twenty-seven out of 34 patients could be analyzed for mutation clearance. We identified 68 somatic mutations at diagnosis (median, 3 mutations per patient; range 1-5) and 22 of these were still detected in 16 patients after consolidation therapy with a reliable sensitivity of 0.5% (median, 1 mutation; range 0-3). The most frequent noncleared mutations were found in DNMT3A. However, as persistence of these mutations has recently been shown to be without any impact on relapse risk, we performed survival and relapse risk analysis excluding DNMT3A mutations. Importantly, persistence of non-DNMT3A mutations was associated with a higher risk of AML relapse (7/8 pts versus 6/19 pts; P = .013) and with a shorter relapse-free survival (333 days vs. not reached; log-rank P = .0219). Detection of residual disease by routine targeted parallel sequencing proved feasible and effective as persistence of somatic mutations other than DNMT3A were prognostic for relapse in CN AML.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gaksch L, Kashofer K, Heitzer E, et al. Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. Am J Hematol. 2017. PMID: 28960408. doi:10.1002/ajh.24922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。